clinical trials

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

ABSTRACT This concept was further supported by a small, single-blind, split-face study, in which a cream containing 3% Cannabis seed extract was applied twice daily to the cheeks of patients for 12 weeks. The treatment was found to be efficient in reducing sebum production and erythema compared to the vehicle treated side [124]. Moreover, a …

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System Read More »

Sep 28 2019

Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism.

ABSTRACT The endocannabinoid (eCB) system plays a key role in many physiological and pathological conditions and its dysregulation has been described in several rheumatological and autoimmune diseases. Yet, its possible alteration in systemic lupus erythematosus (SLE) has never been investigated. Here, we aimed filling this gap in plasma and peripheral blood mononuclear cells (PBMCs) of …

Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism. Read More »

Sep 28 2019

Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes

ABSTRACT We additionally found that CBD also prevented the “pro-acne” LA-T combination from elevating the expression of TNFA (Figure 3A), a key cytokine in the pathogenesis of acne vulgaris (2, 24–30). These data suggested that CBD may exert antiinflammatory actions on human sebocytes (as had already been demonstrated for CBD in several other experimental models, …

Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes Read More »

Aug 28 2019

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

ABSTRACT Experimental evidence gathered from preclinical IBD models and conducted in rodents point to a strong potential of the ECS components to serve as drug targets in inflammatory diseases of the intestine. Data suggest a homeostatic role of the ECS in the gut. Accordingly, it is believed that the enhancement of endocannabinoid signaling, as observed …

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Read More »

Aug 26 2019

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism.

Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

JOIN OUR NEWSLETTER

CONNECT WITH US

About

LEARN

Shop

These statements have not been evaluated by the FDA. This product is not intended diagnose, treat, cure or prevent disease.